Salix Pharma (SLXP) Misses Q3 EPS by 3c; Issues Weak Q4 Outlook

Salix Pharma (NASDAQ: SLXP) reported Q3 EPS of $1.53, $0.03 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $354.7 million versus the consensus estimate of $394 million.

Salix Pharma sees FY2014 EPS of $5.20, versus the consensus of $6.17. Salix Pharma sees FY2014 revenue of $1.4 billion, versus the consensus of $1.59 billion.

Salix Pharma sees Q4 2014 EPS of $1.16, versus the consensus of $1.95. Salix Pharma sees Q4 2014 revenue of $325 million, versus the consensus of $436.0 million.

For earnings history and earnings-related data on Salix Pharma (SLXP) click here.

You May Also Be Interested In

• James Hardie Industries plc (JHX) Tops Q1 EPS by 5c ; Offers Guidance
• Kodiak AI, Inc. (KDK) Misses Q2 EPS by 32c
• Overseas Shipholding Group (OSG) Misses Q2 EPS by 9c